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Abstract: The epithelial cell adhesion molecule (EpCAM) is a membrane glycoprotein that is expressed in most
normal human epithelia and overexpressed in most carcinomas. This molecule is responsible for cell-to-cell
adhesion and additionally participates in signalling, cell migration, proliferation and differentiation. Therefore,
EpCAM has been the target of immunotherapy in clinical trials of several solid tumours. It has been found to
play an important role in the detection and isolation of circulating tumour cells (CTCs). The aim of this study
was to investigate and compare the specificity and selectivity of different anti-EpCAM antibodies in order to
assess their usefulness for CTCs binding. All experiments were performed in six different types of breast cancer
cell lines (MCF-7, SkBr-3, T47D, CAMA-1, MDAMB-231, and BT-20) and using three different anti-EpCAM
antibodies (EBA-1, AUA-1, and 9C4). Immunofluorescence and Real-Time PCR techniques were applied to
analyse the protein and gene expression levels. The experiments revealed that the investigated antibodies dif-
fered significantly regarding the specificity of EpCAM antigen binding. The most significant role in targeting
CTCs   was played by the EBA-1 and 9C4 anti-EpCAM antibodies. They revealed the strongest immunofluores-
cent signal among other applied antibodies and/or were specific for all examined breast cancer cell lines. The
strength and specificity of reaction was dependent not only on the type of antibody, but also on the type of breast
cancer cell line. We noted that the diverse sensitivities of reactions depended on the type of applied antibody.
We therefore recommend the simultaneous application of different anti-EpCAM antibodies. An appropriate
choice of anti-EpCAM antibodies and an evaluation of EpCAM expression in breast cancer appear to be cru-
cial, especially as this antigen is being proposed as a marker for the detection of circulating tumour cells. (Folia
Histochemica et Cytobiologica 2012, Vol. 50, No. 4, 534–541)
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Introduction
The epithelial cell adhesion molecule (EpCAM) is
a 40kDa monomeric membrane glycoprotein that is
expressed in most normal human epithelia [1]. Addi-
tionally, EpCAM is overexpressed in the majority of
carcinomas and is, therefore, a potential target for
the immunotherapy of human solid tumours e.g. colo-
rectal cancer [2] and breast cancer [3]. The mole-
cule has also been named AUA1, ESA, GA733,
HEA125, and 323/A3, which describe the same anti-
body that was raised against this molecule [1, 4].
EpCAM functions not only as a homophilic adhesion
protein; it also participates in cell migration, prolif-
eration and differentiation [5–7].
In a number of tumours of epithelial origin, ac-
tive proliferation of cancer cells is associated with
increased in vivo EpCAM expression, which is char-
acteristic for neoplastic transformation of tissues
that normally reveal no or low EpCAM expression
profile, such as squamous epithelium [8, 9]. More-
over, overexpression of EpCAM in breast and ova-
rian cancer often correlates with a poor prognosis
[10, 11]. Osta et al. [5] demonstrated that EpCAM
was highly overexpressed in primary and metastat-
ic breast cancer (by as much as 100-fold compared
to normal breast tissue). Moreover, silencing of
EpCAM gene expression decreases the prolifera-
tion, migration and invasive capacity of breast can-
cer cell lines in vitro.
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Circulating tumour cells (CTCs) are detectable in
blood samples from the majority of cancer patients,
although they are found at very low concentrations
of 10-6-10-7/ml. Hence, several different systems have
been developed for the isolation and characterisation
of CTCs. In most studies, CTCs are defined as being
positive for EpCAM and cytokeratins 8, 18 and 19,
and negative for CD45. Therefore, some CTC enrich-
ment methods are based on the use of anti-EpCAM
antibodies and subsequent detection with anti-cytok-
eratin antibodies [12–14].
Detection of CTCs in the blood of cancer patients
is a non-invasive method that may help in elucidating
how these cells spread through the bloodstream, set-
tle down at distant sites, and form metastases. Identi-
fication of specific subtypes of circulating tumour cells
in peripheral blood of cancer patients can provide
information about the biology of metastasis, and can
be useful in assessing the invasive potency of individ-
ual CTCs. Therefore, it could improve the clinical
management of metastatic cancer patients as a diag-
nostic and prognostic factor [15, 16].
Several dozen antibodies have been raised against
the EpCAM antigen to date [17]. They can bind to dif-
ferent domains of the molecule and show low- or high-
binding affinity. Therefore, the expression levels of the
immunohistochemical EpCAM protein analyses can
be distinct because different types of anti-EpCAM
antibodies can show differing antigen bindings [1].
Looking at all the recorded data, it appears that
EpCAM can play an important role in binding and
detecting circulating tumour cells. Hence, the evalu-
ation of EpCAM expression in primary breast cancer
is crucial for the application of this antigen as a mo-
lecular biomarker. This study aimed to investigate and
compare the specificity and selectivity of different
anti-EpCAM antibodies in order to assess their
ability for CTCs binding. Since the heterogeneity of breast
cancer types was also taken under consideration, six
different breast cancer cell lines were examined. Addi-
tionally, we analysed the differential distribution of
the EpCAM protein within cultured breast cancer
cells as well as of the expression profiling of EpCAM
mRNA.
Material and methods
Cell lines. The following breast cancer cell lines were used
in this study: MCF-7, SkBr-3, T47D, CAMA-1, MDAMB-
231 and BT-20. Two additional cell lines were used as posi-
tive and negative controls. The positive one was EpCAM(+)
human colon cancer cell line (LoVo) (all cell lines were
obtained courtesy of the Institute of Pathology Charite-
Universitatsmedizin Berlin). The latter (negative), was
EpCAM(–) mouse embryonic fibroblast cell line (3T3/balb).
Fibroblast cells have a mesodermal origin and therefore
show no expression of EpCAM.
Cells were routinely cultured in media intended for each
type of cell line (MCF-7, L-15, SkBR-3, MDAMB-231 and
BT-20 – DMEM, T47D and CAMA-1 — RPMI-1640; Sig-
ma-Aldrich). All media were supplemented with 5% fetal
bovine serum (Sigma-Aldrich), L-glutamine (Sigma-Ald-
rich) and 1% antibiotic-antimycotic solution (penicillin,
streptomycin, amphotericin B) (Sigma-Aldrich). Cell lines
were cultured at 37°C in a humidified 5% CO2 atmosphere.
Real-Time PCR technique. Cells were harvested at near-
confluence state from three 75cm2 flasks for each cell line.
Cells were detached from the plastic surface by incubation
in 0.25% sterile-filtered Trypsin-EDTA solution, pelleted
and resuspended in 1ml of TriReagentO (Sigma-Aldrich).
Total cellular RNA was isolated from 3 × 106 cells of each
breast cancer cell line using a modified version of the meth-
od of Chomczynski and Sacchi [18]. The RNA samples were
resuspended in 20 µl of RNase-free water and stored at
–80oC.  RNA samples were reverse-transcribed (RT) into
cDNA (Transcriptor First Stand cDNA synthesis kit, Roche).
RQ-PCR was conducted in a real-time PCR detection sys-
tem (Real-Time PCR 7900HT Fast RT System, Applied Bio-
systems) using SYBR® Green I as detection dye, and target
cDNA was quantified using a relative quantification meth-
od. The relative abundance of EpCAM transcript in each
sample was standardised by the internal standard of beta-
actin (ACTB). For amplification, 2 µl of total cDNA solution
was added to 18 µl of Maxima SYBR Green/ROX qPCR
Master Mix (2 ×) (Fermentas) and primers (Table 1). One
RNA sample of each preparation was processed without the
RT-reaction to provide a negative control in subsequent PCR.
The relative abundance of mRNA expression of EpCAM in
LoVo cell line was used as a positive control. The 3T3 mice
fibroblast cell line which does not express EpCAM was used
as a negative control of EpCAM amplification. Therefore,
all assays of expression patterns of EpCAM in breast cancer
cell lines were referred in relation to LoVo cell line.
To quantify the specific genes expressed in the cell lines,
the levels of expression of specific mRNAs in each sample
were calculated relative to ACTB expression. To ensure the
integrity of these results, the additional housekeeping gene
Ka-tubulin 1 (Ka1), was used as an internal standard to dem-
onstrate that ACTB mRNAs were not regulated differently
in the tested cell lines. Real-Time PCR analysis was per-
formed using the Visual Basic program implemented by
Muller et al. [19].
Immunofluorescence technique. Cell lines were detached
from the plastic surface of 75 cm2 cell culture flasks by incu-
bation with 0.25% sterile-filtered Trypsin-EDTA solution
and resuspended in an appropriate culture medium. Cells
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were counted and placed in groups of 100,000 (105), on glass
slides by centrifugation in Cytospin (10 minutes, 1,000 rpm).
Cells were fixed in 4% paraformaldehyde in PBS for
15 minutes, washed three times in PBS and blocked in 3%
bovine serum albumin for 45 minutes. Primary anti-EpCAM
antibodies (mouse monoclonal anti-human EBA-1, AUA-1,
9C4, 1:100, 1 hour/RT, Santa Cruz Biotechnology) were
used with the respective FITC-labelled secondary anti-
mouse antibody (MFP488, goat anti-mouse IgG, 1:500, 1h/
/RT, MoBiTec). Afterwards, cells were washed three times
with PBS and sealed with DAPI medium. Analysis was made
under a fluorescence microscope (Zeiss Axio-Imager.Z1).
Antigen expression was defined as specific when the stain-
ing signal was present on the tumour cell membrane or/and
in the cytoplasm. The staining intensity of tumour cells was
scored in relation to the staining intensity of control cell




Using Real-Time PCR, we found an increased expre-
ssion of EpCAM in the SkBr-3 cell line compared to
LoVo. Moreover, we observed decreased EpCAM
mRNA levels in MCF-7 (0.87 fold), CAMA-1 (0.49
fold) and T47D (0.23 fold) compared to LoVo. Much
lower expressions of EpCAM mRNA in BT-20 and
MDAMB-231 breast cancer cell lines, (14,600-fold
and 330-fold, respectively), were detected (Table 2;
Figure 1).
Immunofluorescence analysis
Immunofluorescent analysis of six human breast
cancer cell lines showed that they significantly differed
regarding the expression of the EpCAM protein. Diffe-
rences were also observed in relation to three dif-
ferent antibodies used in the experiment (EBA-1,
AUA-1, 9C4) (Table 3). The immunofluorescent anal-
ysis of the EpCAM protein expression revealed
a similar pattern to the EpCAM mRNA profile when
compared to the EBA-1 mAb staining.
A strong positive reaction for EBA-1 was observed
in the SkBr-3, CAMA-1 and T47D cell lines (Fig-
ures 2A, B, C), and a weak signal was observed in the
MCF-7 cell line. The MDAMB-231 and BT-20 cell
lines revealed a lack of immunofluorescent signal for
the EBA-1 antibody.
For the AUA-1 antibody, a moderate signal was
observed only in the SkBr-3 cell line (Figure 3). The
Table 2. Mean normalised EpCAM mRNA expression of triplicates for each breast cancer cell line
Description Mean of triplicates
Mean normalized SE of mean normalized SE of mean normalized
expression  expression  expression in %
LoVo 3.07E-01 1.23E-02 4.00
3T3 1.72E-05 0.00E+00 0.00
MCF-7 2.67E-01 6.05E-03 2.27
BT-20 2.10E-05 2.76E-06 13.19
CAMA-1 1.50E-01 5.77E-03 3.86
T47D 6.95E-02 3.00E-03 4.32
SkBr-3 3.47E-01 2.98E-03 0.86
MDAMB-231 9.24E-04 5.55E-05 6.01
Table 1. Primer sequences used for Real-Time PCR
Gene Sequence Gene ID
EpCAM fwd 5’ GCTGGTGTGTGAACACTGCT 3’
rev 5’ CCAGGATCCAGATCCAGTTG 3’ NM_002354.2
ACTB fwd 5’ TCTGGCACCACACCTTCTAC 3’
rev 5’ GATAGCACAGCCTGGATAGC 3’ NM_001101.3
Ka1 fwd 5’ TGGAACCCACAGTCATTGATG 3’
rev 5’ TGATCTCCTTGCCAATGGTGT 3’ NM_006082
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MCF-7, T47D, CAMA-1, MDAMB-231 and BT-20
cell lines were negative for this antibody.
The third antibody used in this assay was 9C4 (Fi-
gure 4). All the studied cell lines demonstrated a pos-
itive signal with a moderate staining intensity, except
for the Bt-20 cell line, in which the signal was strong.
The positive control cell line, LoVo, revealed a strong
immunofluorescent signal for EBA-1 (Figure 5A),
weak for 9C4 and no signal for AUA-1 antibody. The
































































Expression of EpCAM mRNA in breast cancer cell lines
Figure 1. Mean normalised expression of EpCAM mRNA
in breast cancer cell lines
Table 3. Results of immunofluorescence analysis of EpCAM
protein expression in breast cancer and control cell lines
Cell line Antibody
EBA-1 AUA-1 9C4
MCF-7 + – ++
SkBr-3 +++ ++ ++
T47D +++ – ++
CAMA-1 +++ – ++
MDAMB-231 – – ++
BT-20 – – +++
LoVo +++ – +
3T3 – – –
Intensity score: – no staining, + weak, ++ moderate, +++ strong
Figure 2. Immunocytochemical localisation of EpCAM
with the use of EBA-1 antibody in: A) SkBr-3 breast cancer
cell line; B) CAMA-1 breast cancer cell line; C) T47D
breast cancer cell line. Strong membranous signal visible.
Immunofluorescence technique; FITC — labelling; nuclei
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The immunofluorescent study additionally re-
vealed diverse distribution of EpCAM within the
breast cancer cells lines, which was also related to
the type of applied antibody. Among the EBA-1
positive breast cancer cell lines (SkBr-3, CAMA-1,
T47D), strong specific membrane staining was visi-
ble (Figures 2A, B, C; 5A). The 9C4 positive cell
lines demonstrated mainly cytoplasmic (Figure 4) or/
/and membranous-cytoplasmic (not shown) distribu-
tion of the EpCAM protein, depending on the type
of cell line.
Discussion
EpCAM is not expressed in non-epithelial tumours
(melanomas, sarcomas, lymphomas) but is commonly
overexpressed in cancers of epithelial origin. The
protein is present in human carcinomas of various
origins, including colon, breast, prostate, head and
neck, and liver [10, 20–22].
In this study, Real-Time PCR and immunofluo-
rescence analyses of six human breast cancer cell lines
revealed that these cell lines differed significantly
regarding EpCAM expression. Although more precise
methods for cell phenotyping are available (e.g. flow
cytometry), in this study immunofluorescence analysis
was performed. Tested cell lines were of an adherent
type, and therefore the necessary step in their flow
cytometry analysis is to detach them from the culture
dish surface and separate very carefully. In our study,
Figure 3. Immunocytochemical localisation of EpCAM
with the use of AUA-1 antibody in SkBr-3 breast cancer
cell line. Moderate membranous-cytoplasmic signal visible.
Immunofluorescence technique; FITC — labelling; nuclei
counterstained with DAPI. Objective 20 ×
Figure 4. Immunocytochemical localisation of EpCAM
with the use of 9C4 antibody in BT-20 breast cancer cell
line. Strong cytoplasmic signal visible. Immunofluorescence
technique; FITC — labelling; nuclei counterstained with
DAPI. Objective 20 ×
Figure 5. Immunocytochemical localisation of EpCAM
with the use of EBA-1 antibody in control cell lines: A)
LoVo cell line — positive control, B) 3T3/balb cell line —
negative control. Immunofluorescence technique; FITC —
labelling; nuclei counterstained with DAPI. Objective 20 ×
A
B
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cells were detached without separation, and left in
a cluster form.
We found differences in EpCAM expression es-
pecially in relation to three different anti-EpCAM
antibodies used in the experiment (EBA-1, AUA-1,
9C4). The strength and specificity of reaction was
dependent not only on the type of antibody, but also
on the type of breast cancer cell line. It was shown by
Baeuerle et al. that the prognostic value of EpCAM
expression depended not only on tumour type, but
also on disease stage, tumour  microenvironment, and
host antitumour immunity [4].
In this study, we found that the EBA-1 antibody
revealed the strongest signal, but not for all types of
examined cultured cells. Therefore, for immuno-
histochemical measurement of EpCAM protein ex-
pression, applied as a marker of cancer invasiveness,
not only the histological subtype of cancer affects the
reaction specificity, but also the type of antibody
should be taken into account.
Our findings suggest that the best way to obtain
the most specific results could be the simultaneous
application of different anti-EpCAM antibodies. In
the case of the studied breast cancer cell lines, this
would be a mixture of EBA-1 and 9C4 antibodies.
Additionally, EpCAM immunohistochemistry could
be used as a diagnostic factor in the assessment of
aberrant tissue morphology.
EpCAM is widely expressed in intensely prolifer-
ating cells of the intestitial epithelium [6]. An overex-
pression of EpCAM has been frequently demonstra-
ted in different types of colorectal carcinomas [23].
Therefore, as a positive control in the experiment,
the human colon adenocarcinoma cell line, LoVo, was
used. The pattern of EpCAM immunoreactivity
within the cell was found to be different in carcinoma
cells compared to normal epithelia. In epithelial cells,
this molecule is mostly expressed on the basal or ba-
solateral cell membrane, and is located predominantly
in the intercellular spaces where epithelial cells form
very tight junctions [24]. However, in the present
study, the EpCAM molecules were present at all sur-
faces of cultured breast cancer cells, especially adja-
cent cells, and showed high immunoreactivity at the
cell-cell boundaries. Such overexpression of the
EpCAM molecule is regarded as an important mecha-
nism in disrupting cell-to-cell contacts, and thus en-
abling the cell migration required for the develop-
ment of metastases. Therefore, the EpCAM might
be considered to represent a prometastatic molecule.
The cellular localisation of EpCAM expression
can be an important diagnostic factor in differenti-
ating the type of carcinoma. A subcellular redistri-
bution of EpCAM from basolateral localisation in
normal tissues to various compartments in cancer
cells could also play a role in a differential activa-
tion of EpCAM [25].
Similarly to the data of Gostner et al. [26], locali-
sation of EpCAM in the cell was determined by cell
culture density. We also found that highly confluent
monolayers showed strong membranous EpCAM
expression, while separated cells exhibited a much
weaker signal. Additionally, differences in the locali-
sation of EpCAM in cultured cells were observed, and
were related to the type of applied antibody (i.e. EBA-1
— membranous, AUA-1, 9C4 — membranous and
cytoplasmic).
In a large group of primary breast cancers, high
levels of EpCAM expression correlated with a larger
tumour size and lymph node metastases [27]. In ad-
dition, it was also associated with proliferative activi-
ty and contributed to neoplastic transformation [1,
8, 9]. According to Gastl et al., the overexpression of
EpCAM in breast cancer is clearly associated with
poor disease-free and overall survival [28].
Cancer cells detached from the primary tumour
site enter the circulatory system, which results in me-
tastases to distant organs e.g. lymph nodes. These
cells, known as circulating tumour cells (CTCs), are
detectable in blood samples from patients with meta-
static cancer. Detection of CTCs in blood is a nonin-
vasive method of sampling and studying tumour cells
compared to classic biopsy. Most CTCs enrichment
methods are based on the use of EpCAM-specific
antibodies and subsequent detection using anti-cytok-
eratin [13, 14, 29, 30]. EpCAM is a surface marker
found only on carcinoma cells. Nevertheless, to min-
imise the possibility of false-positive or false-negative
results, a system of precisely evaluated diagnostic
antibodies must be applied (e.g. pan-anti-cytokeratin
antibody, a tumour-specific anti-EpCAM antibody).
The results of our study prove that not every type
of anti-EpCAM antibody is suitable for targeting
cancer cells in different types of breast carcinomas.
As mentioned earlier, not only the level of EpCAM
expression but also the distribution of this protein
within the cell is an important factor in order to de-
tect CTCs. Therefore, a more valuable type of anti-
body for the isolation of CTCs would be an antibody
that is highly specific to the extracellular domain of
EpCAM molecule (in this case, EBA-1).
Of all tumour types, CTCs have been most thor-
oughly investigated in breast cancer [14, 31, 32]. This
provided the rationale for our studies on breast can-
cer cell lines. The detection of CTCs may predict the
presence of micrometastases and may provide an ear-
lier indication of disease status than body imaging
methods. The detection of CTCs at the time of diag-
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nosis may also help predict which patients would ben-
efit most from different therapeutic strategies, e.g.
from chemotherapy.
The aim of this study was also to analyse mRNA
expression to compare the potential prognostic rele-
vance of EpCAM mRNA and the immunoreactivity
of this protein. In the studied breast cancer cell lines,
we found an association between the intensity of im-
munostaining and EpCAM mRNA expression levels,
especially with the EBA-1antibody. The results of our
study support the results of other investigators who
validated EpCAM mRNA expression in untreated
node-negative breast cancer patients. They also dem-
onstrated the association between high and low
mRNA expression and high and low immunostaining
levels, respectively [33]. Therefore, the analysis of the
EpCAM mRNA expression can serve as an addition-
al valuable, precise and sensitive method of EpCAM
expression evaluation, because mRNA expression is
not always followed by respective protein expression.
Moreover, measurements of antigens’ mRNA can-
not provide data on the protein distribution within
the cells which is essential for the use of EpCAM
antigen for CTCs binding.
In conclusion, the EBA-1 and 9C4 anti-EpCAM
antibodies may play a significant role in targeting circu-
lating tumour cells. The former, because it provided
the strongest immunofluorescent signal of all the
other tested antibodies. The latter, because it was
specific for all examined breast cancer cell lines.
However, the diversity of reaction sensitivity de-
pends on the type of applied antibody. Therefore, the
simultaneous application of different anti-EpCAM
antibodies is recommended. Thus, an appropriate
choice of the anti-EpCAM antibodies and evaluation
of EpCAM expression in breast cancer appears to be
crucial, especially as it is proposed that this antigen
be used as a marker to detect circulating tumour cells.
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